PHIO.US Phio Pharmaceuticals Corp

Healthcare Biotechnology USA Stocks
0.7522 USD
Close of Nov 16, 2026
0.7198 1.88
Market cap
USD 8.99M
P/E
-
P/B
1.07x
ROE
-190.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PHIO.US undervalued?

Graham number

The Graham number of Phio Pharmaceuticals Corp cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Phio Pharmaceuticals Corp fundamental analysis

No fundamental analysis for Phio Pharmaceuticals Corp yet.

Phio Pharmaceuticals Corp stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Phio Pharmaceuticals Corp

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was…

Full company profile